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Tumors have evolved mechanisms to escape anti-tumor immunosurveillance. They limit
humoral and cellular immune activities in the stroma and render tumors resistant to
immunotherapy. Sensitizing tumor cells to immune attack is an important strategy to revert
immunosuppression. However, the underlying mechanisms of immune escape are still poorly
understood. Here we discover Indoleamine-2,3-dioxygenase-1 (IDO1)+ Paneth cells in the
stem cell niche of intestinal crypts and tumors, which promoted immune escape of colorectal
cancer (CRC). Ido1 expression in Paneth cells was strictly Stat1 dependent. Loss of IDO1+
Paneth cells in murine intestinal adenomas with tumor cell-specific Stat1 deletion had pro-
found effects on the intratumoral immune cell composition. Patient samples and TCGA
expression data suggested corresponding cells in human colorectal tumors. Thus, our data
uncovered an immune escape mechanism of CRC and identify IDO1+ Paneth cells as a target
for immunotherapy.
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Colorectal cancer (CRC) is the third most common cancerworldwide and patients with metastases in distant organshave a 5-year survival rate below 13%1. Metastatic CRC is
currently treated with several combinations of cytotoxic agents.
They improved overall survival of patients, treated initially with
fluoropyrimidine monotherapy, from 12 to 30 months2. How-
ever, chemotherapy reached its limits3, which fostered clinical
trials for immunotherapies4. The importance of immuno-
surveillance in CRC is emphasized by the good prognostic value
of CD3+, CD8+, and CD45RO+ T-cell infiltration (Immuno-
score)5–7. Unfortunately, immunotherapy with checkpoint inhi-
bitors showed clinical benefits only in mismatch-repair-deficient
CRC with high neo-antigen load. Durable responses in CRC with
different etiologies remained scarce, which is due to immune
escape mechanisms8.
The transcription factor signal transducer and activator of
transcription 1 (Stat1) is a key effector in tumor immuno-
surveillance mediated by natural killer (NK)- and T cells9,10.
Consistently, Stat1 is part of the immunologic constant of rejec-
tion gene expression signature, which correlates with good
prognosis of CRC7. In cancer cells, Stat1 inhibits proliferation and
promotes apoptosis via induction of cyclin-dependent kinase
inhibitors and pro-apoptotic proteins9. Stat1 also regulates the
expression of tissue antigens and proteins of the antigen pre-
sentation machinery, which enhance the immunogenicity of
tumors11. Therefore, it is generally considered that Stat1
expression and activation in immune cells and in cancer cells
suppresses tumorigenesis. Type I and II interferon (IFN) are the
major activators of canonical Stat1 signaling, which relies on
Tyr701 phosphorylation (pY-STAT1) and mediates tumor sup-
pressive effects of IFN12. However, the tumor cell-intrinsic role of
Stat1 in CRC is not well defined.
Lgr5+ stem cells at the bottom of intestinal crypts have been
identified as possible precursor cells for CRC13. However, non-
stem cells can also acquire tumor-initiating capacity14 and Lgr5+
cancer stem cells are not essential for growth of primary
tumors15. These cells are separated by Lysozyme+ Paneth cells in
the small intestine, which provide essential niche factors for stem
cell proliferation and self-renewal16. In the colon, Lysozyme−
deep crypt base secretory cells support Lgr5+ stem cells16 but
colonic Paneth cells can appear through epithelial metaplasia17.
Paneth cells have been identified in intestinal tumors of ApcMin
mice18 and in sporadic CRC of humans, albeit at varying fre-
quencies ranging from 0.2% to 39%19. However, intestinal tumors
from familial adenomatous polyposis (FAP) patients with
inherited Apc mutations harbored more than 90% of Paneth
cells20. The role of Paneth cells is unclear but CRC developed
predominantly in colonic mucosal tissue with Paneth cell meta-
plasia21 and the presence of Paneth cell-containing adenomas
increased the risk for synchronous CRC19. Therefore, Paneth cells
might promote CRC formation.
Here we identified a subset of Paneth cells that displayed Stat1-
dependent expression of the immune checkpoint molecule IDO1.
Loss of these cells in Stat1-deficient intestinal tumors of ApcMin
mice resulted in reduced tumor load and increased infiltration of
anti-tumor immune cells.
Results
Epithelial Stat1 promotes formation of intestinal tumors. We
used ApcMin mice22 with conditional deletion of Stat1 in intest-
inal epithelial cells (Stat1ΔIEC ApcMin)23,24 to identify Stat1
functions in intestinal tumorigenesis. Deletion of Stat1 was con-
firmed by PCR (Supplementary Fig. 1a), quantitative PCR
(qPCR) of purified intestinal epithelial cells (Supplementary
Fig. 1b) and immunohistochemistry (IHC, Supplementary
Fig. 1c). Lamina propria cells of Stat1ΔIEC ApcMin mice displayed
STAT1 expression, which demonstrated specific ablation in
intestinal epithelial cells (Supplementary Fig. 1c). Goblet, enter-
oendocrine, Paneth, and proliferating cells in the intestinal crypts
were present at normal numbers in Stat1ΔIEC ApcMin mice
(Supplementary Fig. 1d-h). These data show that epithelial cell-
specific deletion of Stat1 does not affect intestinal cell differ-
entiation and crypt proliferation of ApcMin mice.
Four-month-old Stat1flox/flox ApcMin and Stat1ΔIEC ApcMin
mice were used to investigate epithelial cell-intrinsic functions of
Stat1 in intestinal tumorigenesis. Tumor formation was reduced
in Stat1ΔIEC ApcMin male and female mice (Fig. 1a–c). Angiogen-
esis (Supplementary Fig. 2a), tumor cell proliferation, and
apoptosis (Supplementary Fig. 2b) were not affected but numbers
of low-grade adenomas were increased (Fig. 1d). These data show
that epithelial cell-intrinsic Stat1 promotes the formation and
progression of intestinal tumors in ApcMin mice.
ApcMin mice develop tumors mainly in the small intestine but
also in the colon25. Similarly, we found tumors in the small
intestine and the colon and stained them for STAT1 by IHC.
STAT1 was detected in tumor and stroma cells of Stat1flox/flox
ApcMin mice. In contrast, STAT1 was not detectable in tumor
cells of Stat1ΔIEC ApcMin tumors demonstrating efficient condi-
tional deletion (Fig. 1e–g). However, Stat1ΔIEC ApcMin tumors
displayed a significant upregulation of STAT1 in the tumor
stroma (Fig. 1e, g). Numbers of STAT3- and activated pY-
STAT3-positive cells were not changed in Stat1ΔIEC ApcMin
tumors (Supplementary Fig. 2c-e). These data show that tumor
cell-intrinsic Stat1 suppresses upregulation of Stat1 in the stroma
of ApcMin tumors.
Tumor cell-intrinsic Stat1 suppresses immune cell activation.
We have recently shown that enhanced anti-tumor immune cell
activity is reflected by increased stromal Stat1 expression in
azoxymethane-dextran sodium sulfate (AOM-DSS)-induced col-
orectal tumors26. Therefore, we investigated immune cell activa-
tion in Stat1ΔIEC ApcMin tumors. As human intestinal tumors
develop mainly in the colon, we performed RNA sequencing
(RNA-seq) experiments with murine colon tumors (Supplemen-
tary Data 1 and 2). The analyses showed reduced expression of
several IFN-stimulated genes (ISGs) in Stat1ΔIEC ApcMin tumors
(Supplementary Data 1). In particular, 24 out of 49 orthologs of
human genes of the IFN-related gene signature for DNA damage
(IRDS)27 were downregulated in Stat1ΔIEC ApcMin tumors
(Fig. 1i–j and Supplementary Data 1). We analyzed The Cancer
Genome Atlas (TCGA) data to evaluate whether these genes are
also regulated by Stat1 in human CRC. A correlation analysis
revealed 529 genes that are co-expressed with Stat1 in human
CRC (Supplementary Table 1). Among them were 16 IRDS genes.
A Venn diagram using (i) human IRDS genes27, (ii) orthologs of
human IRDS genes, significantly downregulated in Stat1ΔIEC
ApcMin mouse tumors, and (iii) the 529 genes, identified to be co-
expressed with Stat1 in the CRC TCGA dataset, revealed a sub-
stantial overlap. A signature of 13 genes was present in all three
gene sets (Fig. 1h). Gene Ontology (GO) term-enrichment ana-
lyses of deregulated genes in Stat1ΔIEC ApcMin tumors and genes
that are co-expressed with Stat1 in human CRC showed a sub-
stantial overlap of GO terms and revealed mainly pathways
implicated in immunological processes (Supplementary Data 3
and 4). These data suggest that Stat1 target genes and Stat1-
dependent regulation of immunological processes are similar in
human and murine CRC.
Among the most significantly downregulated modulators of
immune responses in Stat1ΔIEC ApcMin tumors was the enzyme
Indoleamine-2,3-dioxygenase-1 (Ido1, Fig. 1j, Supplementary
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Fig. 3a, and Supplementary Data 1), which acts as an immune
checkpoint28. Other immune checkpoints were not deregulated in
Stat1ΔIEC ApcMin tumors but expression of the T-cell activation
marker CD28 was increased (Supplementary Fig. 3a). IDO1
converts tryptophan into the immune-suppressive metabolite
kynurenine. Consistently, levels of kynurenine were reduced in
supernatants of Stat1ΔIEC ApcMin tumors (Fig. 1k). We analyzed
expression of inducible nitric oxide synthase (iNOS) and the
serine protease Granzyme B, because they are markers for
activation of several immune cells such as macrophages, mature
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Fig. 1 Reduced intestinal tumor burden in Stat1ΔIEC ApcMin mice. a–c Quantification of tumor load (a), number (b), and mean area (c) in Stat1flox/flox
ApcMin (7♀, 9♂) and Stat1ΔIEC ApcMin (6♀, 13♂) mice. d Grading of tumors in Stat1flox/flox ApcMin (115 tumors, 9 mice) and Stat1ΔIEC ApcMin (68 tumors,
9 mice) mice. Low grade: p < 0.001; high grade: p < 0.001; carcinoma: p= 0.473. e IHC staining demonstrating STAT1+ tumor cells (arrowheads) in
Stat1flox/flox ApcMin colon tumors. STAT1 expression was not detectable in tumor cells of Stat1ΔIEC ApcMin tumors but was increased in the stroma (arrow).
Scale bars indicate 50 µm. f, g Quantification of STAT1+ tumor (f) and stroma (g) cells (f: Stat1flox/flox ApcMin si 12 tumors, 4 mice; colon 13 tumors, 4 mice;
Stat1ΔIEC ApcMin si 12 tumors, 4 mice; colon 12 tumors, 4 mice; g: 24 tumors of 4 mice each). h Venn diagram showing an overlap between human IRDS
genes, IRDS genes downregulated in Stat1ΔIEC ApcMin colon tumors, and genes that positively correlated with Stat1 expression in human CRC TCGA data.
i Heat map of downregulated IRDS genes in Stat1ΔIEC ApcMin colon tumors. j qPCR for Ifi44, Isg15, and Ido1 mRNA expression in colon tumors of
Stat1flox/flox ApcMin (5 mice) and Stat1ΔIEC ApcMin (6 mice) mice (tumors from each mouse were pooled). k ELISA for kynurenine in supernatants of
Stat1flox/flox ApcMin (si: 7 tumors, 5 mice; colon: 7 tumors, 6 mice) and Stat1ΔIEC ApcMin tumors (si: 7 tumors, 7 mice; colon: 7 tumors, 5 mice). l
Quantification of iNOS+ and Granzyme B+ stroma cells (Stat1flox/flox ApcMin iNOS: 12 tumors, 4 mice; GZMB < 0.5 mm2: 9 tumors, 2 mice; >0.5 mm2:
21 tumors, 4 mice; Stat1ΔIEC ApcMin iNOS: 14 tumors, 4 mice; GZMB < 0.5 mm2: 23 tumors, 5 mice; >0.5 mm2: 13 tumors, 3 mice). m, n FACS analysis of
immune cells of Stat1flox/flox ApcMin (pooled tumors of 5 mice in 4 experiments) and Stat1ΔIEC ApcMin (pooled tumors of 4 mice in 4 experiments) colon
tumors. si: small intestine. Bars represent mean ± SEM.
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dendritic cells, cytotoxic T cells, or NK cells. IHC characterization
of the stroma showed increased numbers of activated iNOS+
immune cells (Fig. 1l). Numbers of Granzyme B+ cells were not
significantly changed in large tumors but accumulated in small
adenomas of Stat1ΔIEC ApcMin mice (Fig. 1l and Supplementary
Fig. 3b). Fluorescence-activated cell sorting (FACS) analysis of
T cells demonstrated increased numbers of CD3+, CD4+, and
CD8+ immune cells (Fig. 1m). However, the relative percentage
of Granzyme B+ cells among the CD8+ population was not
changed (Fig. 1n and Supplementary Fig. 3c). As kynurenine
promotes differentiation of regulatory T cells (Tregs)29, we
analyzed CD4+ CD25+ FoxP3+ cell infiltration by FACS. Treg
numbers were significantly reduced in Stat1ΔIEC ApcMin tumors
(Fig. 1n and Supplementary Fig. 3c). It has also been reported that
kynurenine promotes β-catenin nuclear localization in intestinal
cancer cells30,31 but IHC staining revealed unchanged nuclear β-
catenin levels in Stat1ΔIEC ApcMin tumor cells (Supplementary
Fig. 3d). These data suggest that tumor cell-intrinsic Stat1 sup-
presses stroma immune cell activation in ApcMin tumors
through Ido1.
Stat1 promotes Ido1 expression in neoplastic Paneth cells. We
performed IHC and IF staining to assess downregulation of Ido1
in Stat1ΔIEC ApcMin tumors at the cellular level. This analysis
revealed specific IDO1+ tumor cells in Stat1flox/flox ApcMin
tumors that were absent in Stat1ΔIEC ApcMin tumors (Fig. 2a, b,
i). It has been shown that commercially available IDO1 antibodies
are unspecific and unable to detect IDO1 in western blottings32.
To address this issue for IHC staining, we performed in-situ
hybridization (ISH) experiments and verified loss of IDO1+
tumor cells at the RNA level (Fig. 2a). The IDO1+ tumor cells
were arranged in an alternating pattern with IDO1− tumor cells
in neoplastic adenoma sheets (Fig. 2a). A similar arrangement
was described for transformed Lgr5+ stem cells and Lysozyme+
Paneth cells in adenoma sheets of ApcMin tumors, which
resembles crypt organization of the small intestine18. This sug-
gests that IDO1+ tumor cells are either related to stem cells or to
Paneth cells. Co-expression of Lgr5 and Ido1 mRNA was barely
detectable by ISH in Stat1flox/flox ApcMin tumor cells (Fig. 2a),
indicating that IDO1+ cells are Paneth cells. However, the ISH
signals for Lgr5 were weak and not clearly attributable to indi-
vidual cells. Therefore, double immunofluorescence (IF) with
Paneth cell markers was performed. These analyses revealed
protein expression of Paneth cell markers Lysozyme and MMP7
in IDO1+ tumor cells (Fig. 2c, g, h). More than 80% of IDO1+
tumor cells expressed Paneth markers (Fig. 2e, k), indicating that
Paneth cells are the major source for Ido1 expression in the
neoplastic epithelium. Double-positive cells were absent in Sta-
t1ΔIEC ApcMin tumors (Fig. 2c, g) but the overall numbers of
Lysozyme+ and MMP7+ Paneth cells were not reduced (Fig. 2d, j).
Moreover, about 50% of Paneth cells expressed IDO1 in
Stat1flox/flox ApcMin tumors (Fig. 2f, l). These data demonstrate
that Stat1 is required for the formation of IDO1+ Paneth cells in
ApcMin tumors. IDO1+ Paneth cells are potential immunosup-
pressors and their absence might account for immunological
changes in Stat1ΔIEC ApcMin tumors. This assumption is chal-
lenged by the low number of IDO1+ Paneth cells in Stat1flox/flox
ApcMin tumors (Fig. 2b, i). However, we identified a much higher
percentage of IDO1+ Paneth cells in small and early ApcMin
adenomas with almost 30% in the colon (Fig. 2m, n). These data
suggest that IDO1+ Paneth cells support immune escape during
early stages of ApcMin-induced tumorigenesis.
Ido1 is an ISG in human and murine tumor cells33, indicating a
role of canonical Stat1 signaling in the formation of IDO1+
Paneth cells. IHC staining for canonical STAT1 activation
detected <3% pY-STAT1+ tumor cells in Stat1flox/flox ApcMin
tumors (Supplementary Fig. 4a, b). The pY-STAT1+ tumor cells
appeared as cell clusters (Supplementary Fig. 4a), which differed
from the alternating arrangement of IDO1+ Paneth cells. pY-
STAT1 was undetectable in tumor cells of Stat1ΔIEC ApcMin
tumors (Supplementary Fig. 4a, b) but appeared upregulated in
the stroma (Supplementary Fig. 4a, c) similar to upregulation of
total STAT1 (Fig. 1e, g). We blunted type I IFN signaling by
conditional deletion of Ifnar134 in ApcMin tumor cells. Tumor
formation was not affected in the intestine of Ifnar1ΔIEC ApcMin
mice (Supplementary Fig. 4d-f). Moreover, the number of IDO1+
Paneth cells was comparable in Ifnar1flox/flox ApcMin and
Ifnar1ΔIEC ApcMin intestinal tumors (Supplementary Fig. 4g).
These data demonstrate that the formation of IDO1+ Paneth cells
in tumors of ApcMin mice is independent of type I IFN signaling.
We next investigated whether human CRC contain IDO1+
Paneth cells. Biopsies of 149 human T3 and T4 CRC that had not
yet metastasized (Supplementary Table 2) were IHC-stained for
STAT1 and IDO1 to compare staining patterns with Stat1flox/flox
ApcMin mouse tumors. STAT1+ and IDO1+ cancer cells were
readily detectable in human CRC but unlike mouse tumors, IDO1
+ cells did not show an alternating pattern with IDO1− cells
(Fig. 3a). However, a TCGA-based correlation matrix of ISGs
(IRDS genes) and marker genes for cell identities revealed a
correlation between the expression of Stat1, Ido1, and Lysozyme.
Lysozyme clustered with Ido1- and Stat1-regulated IRDS genes
(Fig. 3b). Moreover, we stained 14 early adenomas (5 from FAP
patients) for neoplastic Lysozyme+ IDO1+ Paneth cells. Lyso-
zyme+ and Lysozyme+ IDO1+ Paneth cells were found in ten
adenomas (four from FAP patients) and six adenomas (three
from FAP patients), respectively. In particular, FAP adenomas
showed a perinuclear signal for IDO1 in Paneth cells (Fig. 3c).
The relative contribution of Paneth cells to Ido1 expression was
assessed by IF staining of the six adenomas harboring IDO1+
Paneth cells. About 50% of IDO1+ tumor cells were Lysozyme-
positive, demonstrating a significant contribution of Paneth cells
to Ido1 expression in the neoplastic epithelium (Fig. 3d). In
summary, these data suggest that IDO1+ Paneth cells are present
in human CRC.
IDO1+ CRC cells promote immune escape. Subcutaneous
implantation of C57BL/6-derived MC38 cells into immuno-
competent host mice is an established method for evaluation of
pre-clinical immunotherapy approaches35. We transplanted green
fluorescence protein (GFP)-labeled MC38 CRC cells to test
whether deletion of Ido1 in neoplastic cells mimics immunologic
consequences of IDO1+ Paneth cell ablation in Stat1ΔIEC ApcMin
tumors. Two independent MC38ΔIdo1-GFP subclones
(MC38ΔIdo1-GFP-2 and MC38ΔIdo1-GFP-6) with CRISPR/Cas9-
mediated deletion of the Ido1 locus were generated. The presence
of INDELs in MC38ΔIdo1-GFP cells was verified by sequence
analysis. Both clones contained an additional G in exon 6 of Ido1,
which is a common CRISPR/Cas9-mediated insertion, and
resulted in a truncated IDO1 protein (MC38ΔIdo1-GFP-2 cells are
shown in Supplementary Fig. 5a, b). Sequencing revealed also a
bigger deletion of the genomic locus upstream of the sgRNA
targeting site in MC38ΔIdo1-GFP-2 cells, which might destabilize
the Ido1 mRNA. Commercial antibodies are not suitable to detect
a specific IDO1 protein by western blotting32. However, IFNγ
stimulation induced Ido1 mRNA expression in MC38wt-GFP cells
but not in MC38ΔIdo1-GFP-2 or MC38ΔIdo1-GFP-6 cells (Fig. 4a and
Supplementary Fig. 5c). MC38ΔIdo1-GFP cells displayed a reduced
cumulative cell number (Supplementary Fig. 5d), indicating an
in-vitro proliferation defect similar to human cells31. In vivo,
MC38ΔIdo1-GFP cells formed smaller tumors than MC38wt-GFP
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cells in immunocompetent C57BL/6 hosts (Fig. 4b, c), which were
strongly infiltrated with CD3+ T cells (MC38ΔIdo1-GFP-2 cells are
shown in Fig. 3d, e). In contrast, growth of MC38ΔIdo1-GFP-2 cells
was not affected in immunocompromised NOD scid gamma
(NSG) hosts, which lack mature T cells, B cells, and NK cells
(Fig. 4f, g). We performed transplantation experiments with
mixtures of cells to evaluate protective effects acting in trans.
MC38ΔIdo1-GFP-6 cells were additionally labeled with dsRed to
discriminate them from Ido1-proficient MC38wt-GFP cells. A 1 : 1
mixture of MC38wt-GFP/MC38ΔIdo1-G/RFP-6 cells showed com-
parable growth to MC38wt-GFP cells in immunocompetent
C57BL/6 hosts, indicating that MC38wt-GFP cells restored growth
of MC38ΔIdo1-G/RFP-6 cells in trans (Fig. 4h). IHC staining
detected dsRed-positive cells close to the expected percentage in
mixed tumors (Fig. 4i, j). Moreover, the prominent CD3+ T-cell
infiltration in MC38ΔIdo1-GFP tumors (Fig. 4d, e) was abolished in
mixed tumors (Fig. 4k). IHC staining revealed strong infiltration
of Granzyme B+ immune cells in MC38ΔIdo1-G/RFP-6 tumors,
which was also abolished in mixed tumors (Fig. 4l). These data
demonstrate that Ido1+ MC38 CRC cells are able to promote
immune escape of transplanted tumors.
Tumor cell-intrinsic Stat1-Ido1 favors progression of CRC. We
investigated correlations of STAT1 and IDO1 protein expression
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Fig. 2 Intestinal tumors of Stat1ΔIEC ApcMin mice lack IDO1+ Paneth cells. a IHC staining for IDO1 (upper panel) and double ISH for Ido1 and Lgr5 mRNA
(lower panel) in Stat1flox/flox ApcMin and Stat1ΔIEC ApcMin colon tumors. IDO1+ cells are indicated by arrowheads. Scale bars indicate 20 µm.
b Quantification of IDO1+ tumor cells in IHC-stained tumors of Stat1flox/flox ApcMin (si and colon: 13 tumors, 4 mice) and Stat1ΔIEC ApcMin (si: 12 tumors,
5 mice; colon: 13 tumors, 4 mice) mice. c IF staining for IDO1 and Lysozyme (LYZ1) in Stat1flox/flox ApcMin and Stat1ΔIEC ApcMin colon tumors. Single
fluorescent channels and composites are shown. Positive or double-positive cells are indicated by arrowheads. Scale bars indicate 50 or 10 µm (high-
magnification insets). d Quantification of LYZ1+ tumor cells of Stat1flox/flox ApcMin (si and colon: 12 tumors, 4 mice) and Stat1ΔIEC ApcMin (si: 8 tumors,
colon 12 tumors, 4 mice each) tumors. e, f Quantification of percentages of LYZ1+ IDO1+ tumor cells between IDO1+ (e) and LYZ1+ (f) tumor cells of
Stat1flox/flox ApcMin tumors. g IF staining for IDO1 and MMP7 in Stat1flox/flox ApcMin and Stat1ΔIEC ApcMin colon tumors. Single fluorescent channels and
composites are shown. Positive or double-positive cells are indicated by arrowheads. Scale bars indicate 50 µm. h IF staining for IDO1, MMP7, and E-
Cadherin in Stat1flox/flox ApcMin tumors of the small intestine and colon. Triple-positive cells are indicated by arrowheads. Scale bars indicate 50 µm.
i, j Quantification of IDO1+ (i) and MMP7+ (j) tumor cells in IF-stained tumors of Stat1flox/flox ApcMin (si: 7 tumors, 3 mice; colon: 12 tumors, 3 mice) and
Stat1ΔIEC ApcMin (si: 9 tumors, 3 mice; colon: 11 tumors, 3 mice) mice. k, l Quantification of percentages of MMP7+ IDO1+ tumor cells between IDO1+
(k) and MMP7+ (l) tumor cells of Stat1flox/flox ApcMin tumors. m, n IHC staining (m) and quantification (n) of IDO1+ Paneth cells in early and advanced
Stat1flox/flox ApcMin tumors (si and colon: 12 early adenomas, 5 mice each and 13 advanced tumors, 4 mice each). Scale bars indicate 50 µm. si: small
intestine. n.d.: not detectable. Bars represent mean ± SEM.
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in IHC-stained biopsies of 149 human T3 and T4 CRC (Sup-
plementary Table 2). A score of 0–4 was attributed to STAT1 and
IDO1 levels in tumor and stroma compartments (Supplementary
Fig. 6). STAT1 or IDO1 protein in tumor or stroma cells did not
correlate with overall survival and metastasis-free survival of
patients (Supplementary Table 2). However, a strong correlation
was observed between protein expression of STAT1 and IDO1 in
tumor cells (Fig. 5a) and stroma cells (Fig. 5b). Additional ana-
lysis of TCGA data was used to increase the sample size. A
correlation plot, derived from TCGA data, confirmed strong co-
expression (Spearman score of 0.797) at the RNA level (Fig. 5c).
Patient survival curves for Stat1 and Ido1 were similar (Fig. 5d, e),
which is consistent with the co-expression of both genes. Patients
with Stat1high or Ido1high cancers showed a trend towards
improved survival 50 months after diagnosis (Fig. 5d, e), which
might reflect beneficial effects of Stat1 in stromal immune cell
activation. Consistently, immune metagene signature analysis36
revealed strong infiltration of anti-tumor immune cells in Sta-
t1high tumors (Supplementary Fig. 7a). However, they also
showed increased numbers of Tregs (Supplementary Fig. 7b),
which could be due to tumor cell-intrinsic Stat1-Ido1 expression.
Therefore, we looked for a surrogate marker to discriminate
between tumor cell-intrinsic effects of Stat1-Ido1 expression and
superimposing stromal effects. We have recently identified IFN-
induced Protein with Tetratricopeptide 1 (Ifit1) as a surrogate
marker for Stat1 expression in breast cancer cells, whereas stroma
cells were Ifit1-negative37. We tested whether Ifit1 can also be
employed as a specific surrogate marker for Stat1-Ido1 expression
in the neoplastic epithelium of CRC. IHC staining of human
biopsies demonstrated IFIT1 expression in CRC cancer cells but
not in the tumor stroma (Supplementary Fig. 7c). Importantly,
IFIT1 expression correlated strongly with STAT1 and IDO1
expression in CRC cancer cells (Supplementary Fig. 7c). Scoring
of IDO1 and IFIT1 staining intensities (Supplementary Fig. 7d)
confirmed a strong correlation of protein expression (Supple-
mentary Fig. 7e, Pearson coefficient= 0.541). We first evaluated
the prognostic value of stromal Stat1 expression in Ifit1low
tumors. Ifit1low Stat1low and Ifit1low Stat1high tumors should
display low Stat1-Ido1 expression in the neoplastic epithelium
and low or high Stat1 expression in stroma cells, respectively. The
Ifit1-based stratification significantly improved the prognostic
value of Stat1 expression in CRC (p= 0.03, Fig. 5f). Patients with
Ifit1low CRC benefited from high stromal Stat1 expression
immediately after diagnosis, indicating that low expression of
tumor cell-intrinsic Stat1-Ido1 sensitizes tumors to immune
attack. We next mimicked conditions of our mouse models and
stratified TCGA data into Ifit1high Stat1low and Ifit1low Stat1high
CRC. Ifit1high Stat1low CRC (tumor cell-intrinsic Stat1-Ido1↑,
stromal Stat1↓, similar to Stat1flox/flox ApcMin tumors) displayed a
higher percentage of late-stage IV tumors than Ifit1low Stat1high
CRC (tumor cell-intrinsic Stat1-Ido1↓, stromal Stat1↑, similar to
Stat1ΔIEC ApcMin tumors) (Fig. 5g, h), suggesting that tumor cell-
intrinsic Stat1-Ido1 promotes CRC progression. Moreover, we
employed the DeMixT algorithm38 to deconvolute tumor cell-
intrinsic and stromal expression of Ido1 in TCGA data. We

























































































































































































Fig. 3 Evidence for Ido1-expressing Paneth cells in human CRC and early adenomas. a IHC staining for STAT1 and IDO1 on consecutive tissue microarray
(TMA) sections of human CRC. A tubular structure with cancer cells showing co-expression of STAT1 and IDO1 is indicated by arrowheads in the lower
images (scale bars 50 µm). b Correlation matrix of TCGA expression data for Stat1, Ido1, IRDS genes, and markers for Paneth, Goblet, enteroendocrine, and
cancer stem cells in human CRC. c IF staining for Lysozyme (LYZ) and IDO1 of a human adenoma biopsy of a FAP patient. The perinuclear signal for IDO1 is
indicated by an arrowhead in the right high-magnification image (scale bar 50 µm). d IF staining was used for quantification of IDO1+ non-Paneth (LYZ−)
and Paneth (LYZ+) cells in the neoplastic epithelium of human adenomas.
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subtypes39 and reinvestigated immune cell marker expression.
Similarly, immune cell markers were predominantly expressed in
the stroma. Moreover, the strongest expression was detected in
the stroma of CMS1, a subtype characterized by immune cell
infiltration39, as exemplified for T-cell markers (Supplementary
Fig. 8a, b). Without tumor stroma deconvolution, patients with
Ido1high tumors showed a slight trend towards better prognosis
(Fig. 5d, p= 0.55). After deconvolution, survival curves for
stroma and tumor compartments were laterally reversed (Sup-
plementary Fig. 8c). Patients with strong Ido1 expression in the
neoplastic epithelial cells showed a strong trend (p= 0.074)
towards bad prognosis. Taken together, these data suggest that
tumor cell-intrinsic Stat1-Ido1 expression favors immune escape
and progression of human CRC.
IDO1+ Paneth cells are present in normal crypts. Similar to
tumors, Ido1 mRNA expression was downregulated in small
intestinal and colonic IEC preparations of Stat1ΔIEC ApcMin mice
(Fig. 6a). Therefore, we wondered whether IDO1+ Paneth cells
are present in normal crpyts. IHC and ISH analyses revealed
IDO1+ vesicle-bearing Paneth cells in a subset of crypts of
Stat1flox/flox ApcMin mice (Fig. 6b), which were abolished in
Stat1ΔIEC ApcMin crypts (Fig. 6b, c). We detected up to three
IDO1+ cells in crypts of the small intestine and up to seven cells
in colonic crypts (Fig. 6e). IDO1+ Paneth cells were also iden-
tified in Stat1flox/flox mice (Fig. 6c), demonstrating that their
formation does not depend on the ApcMin allele. They were more
abundant in the distal small intestine, which has a higher bac-
terial load, than in the proximal small intestine (Fig. 6c).
Moreover, their abundance was decreased in mice that were
housed in an extra clean special pathogen-free (SPF) facility and
treated with antibiotics (Fig. 6c). Treated mice also displayed





























































































































































































































Fig. 4 Ablation of Ido1 in MC38 cells interferes with tumor formation in immunocompetent host mice. a qPCR for Ido1 mRNA expression in MC38wt-GFP
and MC38ΔIdo1-GFP-2 cells 0, 1, and 24 h after IFNγ stimulation (n= 3). b, c Tumor size (b) and final tumor weight (c) after subcutaneous injection of
MC38wt-GFP, MC38ΔIdo1-GFP-2, and MC38ΔIdo1-GFP-6 cells into C57BL/6 hosts (MC38wt-GFP: 7 tumors, 7 host mice; MC38ΔIdo1-GFP-2: 7 tumors, 4 host
mice; MC38ΔIdo1-GFP-6: 7 tumors, 7 host mice). d, e IHC staining (d) and quantification (e) of CD3+ infiltrating cells in tumors of MC38wt-GFP (7 tumors)
and MC38ΔIdo1-GFP-2 (6 tumors) cells. f, g Tumor size (f) and final tumor weight (g) of MC38wt-GFP and MC38ΔIdo1-GFP-2 tumors in NSG hosts
(MC38wt-GFP: 15 tumors, 15 host mice; MC38ΔIdo1-GFP-2: 8 tumors, 8 host mice). h Tumor weight of MC38wt-GFP (15 tumors, 15 host mice),
MC38ΔIdo1-G/RFP-6 (8 tumors, 8 host mice), and 1 : 1 mixed tumors (7 tumors, 7 host mice) in C57BL/6 hosts. i, j IHC staining (i) and quantitation (j) of
GFP+ and dsRed(RFP)+ tumor cells in mixed tumors (n= 3). Expected percentages of positive cells are indicated by dashed lines. Scale bars indicate 100
µm. k, l Quantification of CD3+ (k) and Granzyme B+ (l) immune cells in MC38GFP-wt (three tumors each), MC38ΔIdo1-G/RFP-6 (four tumors each), and
mixed tumors (three tumors each). n.d.: not detectable. Bars represent mean ± SEM.
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small intestine (Fig. 6d). These data suggest that the formation of
IDO1+ Paneth cells is induced by the bacterial microbiome.
It was previously shown that the TLR9 agonist ISS DNA can
induce Ido1 in intestinal epithelial cells, which protects from
colitis40. Therefore, we isolated intestinal organoids and stimu-
lated them with immunostimulatory (ISS) DNA (ODN 1668).
Lysozyme staining showed that Paneth cells were present in
organoids but ISS DNA failed to induce Ido1 (Supplementary
Fig. 8d, e). However, bacteria also promote IFNγ production by
CD4+ T cells in the intestinal lamina propria41. IFNγ readily
induced Ido1 in all epithelial cells of organoids at the RNA and
protein level (Fig. 6f, g and Supplementary Fig. 8e). To further
investigate the role IFNγ in vivo, we performed IHC for IDO1 in
intestines of Ifngr1−/− mice42, which lack functional IFNγ
signaling. The number of IDO1+ crypt cells was reduced in
different intestinal parts of Ifngr1−/− mice (Fig. 6h, j).
Interestingly, Ifngr1−/− mice displayed reduced numbers of
Lysozyme+ Paneth cells in the proximal small intestine (Fig. 6i)
similar to mice with antibiotic treatment (Fig. 6d). These data
demonstrate a contribution of IFNγ in induction of IDO1+
Paneth cells.
Our data suggest that a bacteria/IFNγ axis is responsible for
Ido1 induction in Paneth cells. Therefore, we analyzed single-cell
RNA-seq (scRNA-seq) data of Haber et al.43 to investigate the
impact of bacterial infection on Ido1 induction in Paneth cells.
Paneth cell clusters were identified in t-distributed stochastic
neighbor embedding (t-SNE) maps using marker genes (Supple-
mentary Fig. 9a, b). Only two Ido1+ cells were found in t-SNE
maps of healthy mice. Interestingly, they were both allocated to
the Paneth-1 cell cluster, which is located in the distal small
intestine and expresses the marker GM2100243. Haber et al.43
derived also scRNA-seq data from bacteria- and helminth-
Fig. 5 Use of Ifit1 as surrogate marker reveals a negative prognostic value of Stat1-Ido1 expression in the neoplastic epithelium of CRC. a, b One
hundred and forty-nine IHC-stained sections of human CRC were used to assess the correlation between STAT1 and IDO1 protein expression in the tumor
cell compartment (a) and the stroma (b). c Scatter plot of TCGA expression data showing a strong correlation between Stat1 and Ido1 mRNA expression in
human CRC. d–f Patient survival curves for Stat1high/low (d), Ido1high/low (e), and Ifitlow Stat1high/low (f) CRC using TCGA data. The median expression was
used for stratification. g, h Stratification of human CRC into Ifit1low Stat1high and Ifit1high Stat1low cancer subtypes, and correlation with the tumor stage
using TCGA data.
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infected mice. Analysis of these data revealed a prominent
induction of Ido1 in Paneth cells of bacteria- but not helminth-
infected mice (Fig. 7a, b, d, f). Stat1 was induced in both infection
models but more prominently by bacteria (Fig. 7a–c, e). These
data demonstrate that the formation of Ido1+ Paneth cells is
induced by the bacterial microbiome.
Discussion
We identified an immune escape mechanism of CRC that is based
on Stat1-dependent expression of Ido1 in Paneth cells. Paneth cell
markers have previously been linked with intestinal tumorigen-
esis but the significance of the observations remained unclear.
The markers Pla2g2a and Mmp7 were identified as modifiers of
























































































































































































































































Fig. 6 IDO1+ Paneth cells are present in intestinal crypts and reduced in Ifngr1−/− mice. a qPCR for Ido1 mRNA expression in isolated intestinal epithelial
cells of Stat1flox/flox ApcMin (si: n= 4; colon: n= 5) and Stat1ΔIEC ApcMin (si: n= 6; colon: n= 5) mice. b IHC staining for IDO1 (upper images) and double
ISH for Ido1 and Lgr5 (lower images) in the small intestine of Stat1flox/flox ApcMin and Stat1ΔIEC ApcMin mice. IDO1+ Paneth cells are indicated by
arrowheads. Scale bars indicate 20 µm. c–e Quantification of IDO1+ crypts (c), LYZ1+ Paneth cells/crypt (d), and IDO1+ cells/crypt (e) in different
intestinal compartments of co-housed Stat1flox/flox ApcMin (n= 4), Stat1ΔIEC ApcMin (n= 5), Stat1flox/flox (n= 4), Stat1ΔIEC (n= 4), as well as C57BL/6 mice
kept at an extra clean SPF facility with and without ABx treatment (n= 3 each). f qPCR for Ido1 mRNA expression after IFNγ stimulation in intestinal
organoids of Stat1flox/flox (three technical replicates, two mice) and Stat1ΔIEC (three technical replicates, three mice) mice. g IF showing the induction of
IDO1 upon IFNγ stimulation in tumor organoids of Stat1flox/flox ApcMin mice. Scale bars indicate 50 µm. h–j Quantification of IDO1+ crypts (h), LYZ1+
Paneth cells/crypt (i), and IDO1+ cells/crypt (j) in different intestinal compartments of co-housed C57BL/6 (n= 3) and Ifngr1−/− mice (n= 3). n.d.: not
detectable; si: small intestine; SPF: special pathogen free; ABx: antibiotics. Bars represent mean ± SEM.
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function45, interfered with ApcMin-induced tumor formation46.
Moreover, expression of Paneth markers correlated with
increased risk for dietary-induced sporadic intestinal cancer in
mice47 and a Paneth cell-associated gene expression pattern was
identified in human intestinal tumors48. The presence of IDO1+
Paneth cells in intestinal cancers might provide an explanation
for these observations. IDO1 increases local kynurenine levels and
depletes tryptophan. Effector T cells respond to tryptophan
depletion with cell cycle arrest49 and kynurenine promotes Treg
differentiation via the aryl hydrocarbon receptor AhR29. This
promotes an immune-tolerant microenvironment with reduced
CD8+ T-cell activities and expansion of Tregs50–52. Ido1 over-
expression is commonly observed in human CRC and associated
with reduced serum tryptophan levels, whereas kynurenine
metabolites are increased53–55. Localization studies have shown
that Ido1 is expressed by infiltrating myeloid cells and neoplastic
epithelial cells56–58, and both cellular compartments could con-
tribute to kynurenine production. Our results suggest that the
neoplastic epithelium is an important source for kynurenine,
because loss of IDO1+ Paneth cells in Stat1ΔIEC ApcMin tumors
resulted in significantly reduced kynurenine levels that were not
compensated by stromal kynurenine production. We speculate
that neoplastic cells are major producers of kynurenine in tumors,
whereas stromal myeloid cells use different metabolic routes. A
contribution of Ido1-expressing neoplastic epithelial cells to
immune escape has also been found in pancreatic ductal adeno-
carcinomas59 and high Ido1 expression in neoplastic epithelial
cells at the invasive front is an independent adverse prognostic
factor for overall survival and metastasis in CRC58,60,61.
Stat1 is considered as a tumor suppressor in solid cancers9 and
we expected tumors of increased size in Stat1ΔIEC ApcMin mice.
However, tumors were smaller and contained reduced numbers
of Tregs and increased numbers of CD8+ T cells. Similar neo-
plastic and immunologic aberrations were observed in Ido1−/−
ApcMin tumors62. This indicates that loss of IDO1+ Paneth cells
and corresponding immunological consequences surpassed
tumor-promoting effects of Stat1 deletion in Stat1ΔIEC ApcMin
tumors. Interestingly, tumor formation was not affected in Stat1
−/− ApcMin mice63 but this study neglected compensating effects
of stromal Stat1 deletion, which interferes with immuno-
surveillance and alleviates the need for immunosuppression.
Most patients develop sporadic CRC, whereas colitis-associated
CRC (CAC) affects only 1–2% of human cases. Recent studies
demonstrated that specific deletion of Ido1 in intestinal epithelial
cells interfered with AOM-DSS-induced CAC formation in
mice30. The oncogenic function of Ido1 in CAC was attributed to
tumor cell-intrinsic phosphatidylinositol-3-kinase–Akt-mediated
nuclear translocation of β-catenin rather than immunosuppres-
sion30. Our results showed that Stat1 ablation and corresponding
loss of IDO1+ tumor cells did not affect nuclear β-catenin levels
in sporadic ApcMin tumors. This suggests that Ido1 promotes the
formation of sporadic CRC and CAC through different
mechanisms. Moreover, the neoplastic and immunological con-




























































































































Fig. 7 Expression of Ido1 and Stat1 is induced in Paneth cells following bacterial infection. a–d t-SNE maps obtained from single-cell RNA-seq (full-length
sequencing) of 389 epithelial cells from the small intestine of 7–10-week-old C57BL/6J mice without infection (control) and with infection
(Heligmosomoides polygyrus or Salmonella enterica). Three paneth cell-enriched areas, which show increased expression of Ido1 following infection with
Salmonella enterica are highlighted (red circles). e, f Violin plots for the expression of Stat1 and Ido1 (transcripts per million) in Paneth cells with and without
infection. Single-cell RNA-seq data were generated by Haber et al.43 (GEO database: GSE92332). g Model how IDO1+ Paneth cells promote immune
escape of CRC (for details, see discussion). CTL: cytotoxic T lymphocyte; Treg: regulatory T cell.
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sporadic CRC. We found increased AOM-DSS-induced CAC
formation in male Stat1ΔIEC mice64. Stat1ΔIEC tumors contained
reduced numbers of CD8+ T cells64, although IDO1+ Paneth
cells were absent (unpublished data). Therefore, Stat1-dependent
IDO1+ Paneth cells might be particularly important for the
development of sporadic tumors but dispensable for CAC.
It is challenging to deduce prognostic information of tumor
cell-intrinsic Stat1 and Ido1 expression from CRC TCGA data,
because both genes are expressed in neoplastic cells and immune
cells. Correspondingly, good prognosis of CRC patients with
Stat1high tumors might be primarily caused by enhanced anti-
tumor activity of Stat1high immune cells7, whereas prognostic
information of Stat1 expression in neoplastic cells is masked.
Using IHC staining of human samples, we identified IFIT1 as a
surrogate marker for STAT1-IDO1 expression in cancer cells of
human CRC. IFIT1 was not detectable in stromal cells and reg-
ulates the replication of viruses, a function that should not impact
on human CRC prognosis. Ifit1 surrogate expression enabled us
to discriminate between tumor cell-intrinsic and stromal Stat1-
Ido1 functions in bulk gene expression TCGA data. These ana-
lyses suggested that tumor cell-intrinsic Stat1-Ido1 expression
promotes progression of human CRC, correlates positively with
Treg numbers and desensitizes tumors to immune attack.
Moreover, Stat1-Ido1 expression correlated with Lysozyme
expression in human TCGA data and IDO1+ Paneth cells were
present in adenomas of FAP patients, indicating that human CRC
also contain neoplastic IDO1+ Paneth cells.
Stat1-dependent IDO1+ Paneth cells were also found in nor-
mal murine crypts. They did not depend on ApcMin but the
presence of the Min mutation affected their spatial distribution in
the distal small intestine and colon. Extra clean SPF conditions
and treatment of mice with antibiotics substantially reduced the
number of IDO1+ crypts in all parts of the intestine. Moreover,
IDO1+ Paneth cells in normal crypts were enriched in the distal
small intestine, which has a high bacterial load, and we could
identify Ido1 induction in Paneth cells of bacteria-infected mice
using scRNA-seq data. This suggests that IDO1+ Paneth cells are
induced by the local microbiome. TLR9 and IFN signaling are
candidate pathways that could promote Ido1 expression in
Paneth cells. The tumor studies with Ifnar1ΔIEC mice and ISS
DNA-treated organoids suggest that Ido1 is not induced by type I
IFN or TLR9 signaling. In contrast, IFNγ readily induced Ido1 in
epithelial cells of organoids and IDO1+ Paneth cells were reduced
in the intestine of Ifngr1−/− mice. However, in contrast to Sta-
t1ΔIEC mice, IDO1+ Paneth cells were not completely abolished
in Ifngr1−/− mice, indicating that additional factors are impli-
cated in Stat1-Ido1 induction. Ido1 is an IFNγ-inducible gene in
human and murine tumor cell lines33. The microbiome induces
IFNγ production by mucosal T cells in mice41 and in humans65,
and depletion of bacteria reduces IFNγ levels41. This indicates
that interaction of lamina propria cells with the microbiome leads
to the production of type II IFN that induces Stat1-dependent
Ido1 expression in Paneth cells of distinct intestinal crypts.
In summary, we identified Stat1-dependent IDO1+ Paneth
cells in intestinal tumors and normal intestinal crypts. They
might represent bone fide Paneth cells but need Stat1 for Ido1
expression. IDO1+ Paneth cells could act as local immunosup-
pressors to prevent aberrant immune cell activation in response
to bacteria. Hence, they could also provide immune-privileged
niches for tumor formation (Fig. 7g). Early adenomas might use
these niches to shield anti-tumor immune attack during elim-
ination and equilibrium phases of immunoediting. Consistent
with this idea, neoplastic IDO1+ Paneth cells were particularly
abundant in early adenomas of ApcMin mice. Of note, tumor
formation was impaired in ApcMin mice kept under germ-free
conditions66. Targeting IDO1+ Paneth cells might improve
efficacy of immunotherapy in microsatellite-stable CRC patients.
Besides representing a conceptual advance, our findings will
improve precision oncology of CRC.
Methods
Mice. Mice with floxed alleles of Stat124 or Ifnar134 were crossed to Villin-cre
mice23. Villin-cre Stat1flox/flox and Villin-cre Ifnar1flox/flox animals were crossed
with ApcMin mice22 (Jackson Laboratory) to generate Villin-cre Stat1flox/flox Apc-
Min/+ (Stat1ΔIEC ApcMin) and Villin-cre Ifnar1flox/flox ApcMin/+ (Ifnar1ΔIEC Apc-
Min) mice. Mice were kept on a C57BL/6 genetic background and housed under
standard conditions at the Dezentrale Biomedizinische Einrichtung of the Medical
University Vienna (Stat1ΔIEC ApcMin) and the Zentrale Versuchstieranlage of the
Medical University Innsbruck (Ifnar1ΔIEC ApcMin). Experiments were performed
with adult (6–8 weeks old) or tumor-bearing (4 months old) male or female mice.
To deplete commensal gut microbiota, adult wild-type C57BL/6J mice were given
ampicillin (1 g/l), vancomycin (0.5 g/l), neomycin sulfate (1 g/l), and metronidazole
(1 g/l) in drinking water for 28 days. Water was changed every third day to ensure
antibiotic stability. All mouse experiments were performed in accordance with
Austrian and European laws (license numbers BMWFW-66.009/0191-WF/V/3b/
2015 and BMWFW-66.009/0189-WF/V/3b/2015) and with the general regulations
specified by the Good Science Practices guidelines of the Medical Universities
Vienna and Innsbruck.
Human material. Patient material from the Austrian Breast and Colorectal Cancer
Study 91 (ABCSG trial 91, NCT00309543) was used, which is a prospective,
multicenter, randomized trial comparing the efficacy of adjuvant chemotherapy in
stage II colon cancer67. All patients provided written consent and the study was
approved by the ethics committees at the participating institutions.
Isolation of intestinal epithelial cells. Intestinal epithelial cells were isolated from
10–12-week-old mice as described previously68.
Histology, immunohistochemistry, and immunofluorescence. Intestines were
flushed with phosphate-buffered saline (PBS) and 4% paraformaldehyde, fixed and
embedded in paraffin as swiss rolls. Swiss rolls were cut into 2 µm sections and
IHC/IF-stained with standard procedures using antibodies against β-catenin
(Becton Dickinson, 610153, 1 : 80), BrdU (BrdU In-Situ Detection Kit, Becton
Dickinson, 550803), cleaved Caspase 3 (Cell Signaling, 9661, 1 : 200), Endomucin
(eBioscience, 14-5851-82, 1 : 500), GR1 (Serotec, MCA771GA, 1 : 200), Granzyme
B (Abcam, ab4059, 1 : 200), IDO1 (Biolegend, 122402, 1 : 80), iNOS (Biolegend,
610431, 1 : 200), Ki67 (Novocastra, NCL-KI67-P, 1 : 1000), Lysozyme (Dako,
A009902, 1 : 100), p-STAT1 (Cell Signaling, 9167S, 1 : 100), p-STAT3 (Cell Sig-
naling, 9145, 1 : 100), STAT1 (Santa Cruz, sc-592, 1 : 500), STAT3 (Santa Cruz, sc-
7179, 1 : 80), Synaptophysin (GeneTex, GTX100865, 1 : 1000), GFP (Roche,
11814460001, 1 : 1000), red fluorescent protein (RFP) (Rockland antibodies and
assays, 600-401-379S, 1 : 500), CD3 (Neomarker RM9107, 1 : 100), MMP7 (Cell
Signaling, 3801, 1 : 100). IHC staining on human samples was performed using
antibodies against IFIT1 (Sigma Aldrich, HPA055380, 1 : 500), IDO1 (Biolegend,
122402, 1 : 100), p-STAT1 (Cell Signaling, 9167S, 1 : 100), and STAT1 (Cell Sig-
naling, 14994, 1 : 1000).
CRISPR/Cas9 of MC38 cells and transplantation. MC38ΔIdo1-GFP cells were
generated using CRISPR-Cas9 as described previously69. Ido1 exon 6 was targeted
using the following oligos: 5′-CACCTCCTGGTGGGGACTGCGACA-3′ (forward)
and 5′-AAACTGTCGCAGTCCCCACCAGGA-3′ (reverse). Frequency of inser-
tions/deletions in the transfected cell pool was estimated using the TIDE analysis
software. The following primers were used for target site amplification: 5′-
AACTCAGGGCTTTGAGAATGT-3′ and 5′-TTCATCCACTAAGCCACCCC-3′.
Single cells derived from the initially targeted cell pool were expanded indepen-
dently, sequenced for DNA modifications using the above mentioned primers, and
used for transplantation experiments. To label MC38ΔIdo1-GFP cells with dsRed, 10
µg of DsRed-pLenti plasmid (gift from Venugopal Bhaskara), 8 µg of packaging
vector (psPAX2, Addgene plasmid # 12260), 3 µg of envelope vector (pVSV-G,
Addgene plasmid # 14888), and 61 µl of 2 M CaCl2 were diluted to 500 µl in
ddH2O. The solution was then mixed with 500 µl of 2× HBS (50 mM HEPES, 10
mM KCl, 12 mM Dextrose, 280 mM NaCl, 1.5 mM Na2HPO4 pH 7.05) and
incubated for 10 min at room temperature, before being added to HEK293T cells
for virus production. Target cells were incubated with virus containing supernatant
for 5 days. Cells 106 were injected subcutaneously into the flanks of 8–9-week-old
male C57BL/6J mice or NSG mice. To account for host effects, cells of different
genotypes were implanted in the left and right flanks of the same mouse. Mixed
MC38wt-GFP/MC38ΔIdo1-G/RFP tumors were evaluated for the presence of GFP- and
RFP-positive cells via IHC. Individual MC38wt-GFP and MC38ΔIdo1-G/RFP tumors
with 100% GFP+ or GFP+/dsRed+ cells were used for normalization of data.
MC38 cell stimulation. MC38wt-GFP and MC38ΔIdo1-GFP cells were cultured in
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum (FCS), 1%
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Penicillin/Streptomycin (10,000 U/ml) and 1% L-glutamine (200 mM). At 70–80%
confluency, cells were stimulated with 100 ng/µl IFNγ (Immunotools, 12343536)
for 1 h and 24 h, in triplicates.
Quantification and grading of ApcMin tumors. Swiss rolls were stained with
hematoxylin and eosin, scanned with a Pannoramic Midi Slide Scanner (3D His-
tec), and histomorphometrically analyzed with DefiniensTM Developer software
(Definiens). Grading was performed by a board certified pathologist (L.K.).
Flow cytometry. Intestinal tumors from single mice were pooled, minced and
digested in 2 ml PBS containing 0.25% (v/v) FCS and 0.25% (w/v) collagenase IV
(Life technologies, 17104-019) for 45’ at 37 °C under shaking. After straining
through a 70 µm mesh and washing twice with 30 ml PBS, cells were incubated
with TruStain fcX (Biolegend, 101320) and Zombie Aqua Fixable Viability Kit
(Biolegend, 423102). Extracellular staining was performed using antibodies against
CD8a (Biolegend, 100728), CD45 (Biolegend, 103128), CD4 (Biolegend, 100408),
CD3e (eBioscience, 35-0031-82), and CD25 (eBioscience, 25-0251-81). Cells were
fixed (Fixation/Permeabilization Buffer, eBioscience, 00-5123-43), permeabilized
(Permeabilization Buffer, eBioscience, 00-8333-56), and intracellular staining of
FOXP3 (Biolegend, 320011) and Granzyme B (Biolegend, 515405) was performed.
Data were collected using a FACS Fortessa (BD) and analyzed with FlowJo
software.
Enzyme-linked immunosorbent assay. Single tumors of the small intestine and
colon were homogenized in 60 µl PBS and centrifuged. Supernatants were used for
kynurenine ELISA (EMELCA Bioscience, MBS043489) according to the manu-
facturer’s instructions. The results were normalized for the amount of protein.
In-situ hybridization. Duplex ISH was performed on formalin-fixed paraffin-
embedded tissue samples using RNAscope 2.5 HD assay (ACD, 322436) with
probes against Lgr5 (ACD, 312171) and Ido1 (ACD, 315971) according to the
manufacturer’s instructions.
RNA sequencing. Total RNA from tumors was extracted using TRIzol Reagent
(Thermo Fisher Scientific, 15596018) and processed for sequencing using the
TruSeq RNA Sample Preparation Kit (Illumina, Inc.) according to the manu-
facturer’s protocol. mRNA was purified using poly(T)-oligo-attached magnetic
beads, fragmented, and applied to first-strand complementary DNA (cDNA)
synthesis. Second-strand cDNA synthesis was performed using DNA polymerase I
and RNase H. cDNA was end-repaired, A-tailed, ligated to adapters, and amplified
to create the final cDNA library for sequencing (HiSeq2000, Illumina, Inc).
TopHat2 algorithm was used to align raw RNA-seq data to mm10. Aligned bam
files were deposited in ArrayExpress database (E-MTAB-5083). Differentially
expressed genes were identified using DeSeq2 algorithm. An adjusted p < 0.005 and
a fold change >2 or <−2 were defined as cut-off for differentially expressed genes.
GO enrichment analyses were performed using GOrilla software.
scRNA-seq analysis. Pre-processed droplet-based scRNA-seq datasets from
Haber et al.43 (GEO; GSE92332) were re-analyzed using the R package Seurat. For
comparison of Ido1 expression in Paneth cell clusters, the infection model datasets
“SH_Salmonella” and “SH_Hpoly” were used, as well as the according control sets.
Different infection durations (3 days and 10 days) within the “SH_Hpoly” dataset
were pooled. Furthermore, sequencing data of intestinal cells, specifically sorted
with focus on large cells to improve Paneth cell yield, were analyzed. Dimen-
sionality reduction was performed using gene expression data for a subset of
variable genes. The variable genes were selected based on dispersion of binned
variance to mean expression ratios using FindVariableGenes function of Seurat70
followed by filtering of ribosomal protein and mitochondrial genes. Next, principal
component analysis (PCA) was performed and the data were reduced to the top 15
PCA (infection model)/10 PCA (large cells) components (number of components
was chosen based on SDs of the principal components—in a plateau region of an
elbow plot). Graph-based clustering of the PCA reduced data with the Louvain
Method was used after computing a shared nearest-neighbor graph70. The clusters
were visualized on a two-dimensional map produced with t-SNE. The VlnPlot
function was applied to show expression probability distributions across the
clusters and the FeaturePlot function to visualize feature expression within the
clusters on a t-SNE plot. These methods were performed for marker genes of our
cells of interest to identify Paneth and goblet cell clusters. Violin plot expression
levels are depicted on a log transcripts per million (TPM) scale per cluster. Feature
plot depicts a color scale for average gene expression. To identify further clusters
containing Ido1+ cells (TA/Stem, Tuft, enterocytes), the top 50 specific marker
genes for each cluster identified and described in Haber et al.43 were selected using
the CaseMatch function and aggregated and matched to gene expression profiles of
the clusters identified within this analysis using the MetaFeature function (calcu-
lation of relative contribution of each feature to each cell for given set of features).
Polymerase chain reaction. Wild-type, floxed and deleted Stat1 alleles were
amplified using 5′-TAGGCTCCCTCTTTCCCTTC-3′, 5′-
ACACCATTGGCTTCACCTTC-3′, and 5′-CCCCTGTCATCTGGAGTGAT-3′
primers. The Cre transgene was detected with 5′-CGGTCGATGCAACGAGT-
GATGAGG-3′ and 5′-CCAGAGACGGAAATCCATCGCTCG-3′ primers. ApcMin
genotyping was performed using 5′-TCTCGTTCTGAGAAAGACAGAAGCT-3′
and 5′-TGATACTTCTTCCAAAGCTTTGGCTAT-3′ primers, and digestion of
amplicons with HindIII.
Quantitative PCR. RNA was isolated with TRIzol (Life Technologies, 15596-018)
and reverse transcribed with QuantiTect Reverse Transcription Kit (Qiagen,
205313). qPCR was performed using Fast SYBR Green Mastermix (Thermo Fisher
Scientific, 4385616) and Applied Biosystems 7500 Fast Real Time PCR System with
primers 5′-TGGTGAAATTGCAAGAGCTG-3′ and 5′-TGTGTGCGTACCCAA-
GATGT-3′ for Stat1, 5′-ATGTGGGCTTTGCTCTACCA-3′ and 5′-AAGCTGCCC
GTTCTCAATCA-3′ for Ido1, and 5′-TGTTTGTGATGGGTGTG-3′ and 5′-TAC
TTGGCAGGTTTCTC-3′ for Gapdh.
Statistics and reproducibility. Sample sizes and numbers of replicates are
described in detail in the figure legends. Biological replicates were defined as
parallel measurements of biologically distinct samples (mice in most cases). Each
experiment was repeated at least three times. All values are given as means ± SEM.
Normal distribution of data was tested and appropriate tests were performed:
comparisons of two groups were calculated with unpaired Student’s t-test or
Mann–Whitney U-test. For more than two groups, one-way analysis of variance
and Bonferroni’s post-hoc test or Kruskal–Wallis test, and Dunn’s post-hoc test
were used. For analysis of the tumor and TMA gradings, χ2-test was used. Survival
analyses using clinical data from CRC TCGA patients were performed using log-
rank testing and GraphPad Prism 6 software. Correlation analyses of TCGA data
were calculated using cor function of R3.2.1 software and visualization was per-
formed using corrplot and ggplot2 packages. No sample size estimation was per-
formed. Samples were excluded as outliers according to Grubbs’ test (α= 0.05).
Experiments were performed and analyzed in a blinded, randomized manner.
Significant differences between experimental groups are stated as: *p < 0.05,
**p < 0.01, ***p < 0.001, or ****p < 0.0001.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNA sequencing data were deposited in ArrayExpress database, accession number E-
MTAB-5083. Previously generated single-cell RNA sequencing data analyzed here can be
found in GEO (GSE92332). Processed (MapSplice aligned, RSEM quantified and upper-
quartile normalization standardized; Level 3 RnaSeqV2) RNA sequencing data of the
COADREAD dataset were obtained from The Cancer Genome Atlas (TCGA) database.
All other data that support the findings of this study are available from the corresponding
author upon reasonable request.
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